echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The total sales of the four neurosystemic drugs exceeded 5 billion yuan. Who can get through the red line of consistency evaluation in the first batch?

    The total sales of the four neurosystemic drugs exceeded 5 billion yuan. Who can get through the red line of consistency evaluation in the first batch?

    • Last Update: 2017-12-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Highlights on November 29, the news that the first batch of generic drug conformity evaluation varieties were started due to the on-site inspection attracted the attention of the industry Some securities companies made relevant predictions Among the six provinces involved in the first batch of on-site inspection, about 13 varieties of 9 pharmaceutical companies are currently in the state of application and approval Among the 13 "great fever" varieties, 4 are nervous system drugs, among which 3 are psychostimulants, including escitalopram oxalate tablets, sertraline hydrochloride tablets and amitriptyline hydrochloride tablets, and 1 is a psychostatic drug, olanzapine tablets In 2016, the sales of escitalopram oxalate tablets were close to 1.25 billion yuan in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminal chemical drug market, The sales volume of sertraline hydrochloride tablets is more than 680 million yuan, amitriptyline hydrochloride tablets is 11.04 million yuan, olanzapine tablets is 3.21 billion yuan, and the total sales volume of the four products is more than 5 billion yuan   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the market scale of neurosystemic drugs has exceeded 90 billion yuan According to the data of MI nei.com, the market scale of terminal chemical drugs and neurosystemic drugs in public medical institutions in China reached 96.329 billion yuan in 2016, with a growth rate of 9.48% The market scale of this sub category ranks sixth in the whole chemical drug market Among them, psychostimulants accounted for the largest market share in neurosystemic drugs, with a growth rate of 9.82% and a sales volume of 30.843 billion yuan in 2016, while antipsychotic drugs accounted for 10.8% and a sales volume of 10.406 billion yuan in 2016, with a growth rate of 13.28%   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the annual sales of three psychostimulants exceeds 1 billion Table 1: the sales of three psychostimulants in the terminals of public medical institutions in China (data source: minenet China public medical institutions terminal competition pattern) Figure 1: the sales of escitalopram oxalate tablets in the terminals of public medical institutions in China in recent years (unit: 10000 yuan) (data source: terminal competition pattern of China's public medical institutions on the Internet) Figure 2: brand pattern of escitalopram oxalate tablets as the terminal chemical in China's public medical institutions in 2016 (data source: terminal competition pattern of China's public medical institutions on the Internet) data shows that escitalopram oxalate tablets in 2015 The sales volume in the terminal chemical drug market of public medical institutions in China has exceeded the 1 billion yuan threshold, and continued to rise in 2016, with a growth rate of 16.56% The leading enterprise in the market is Lingbei, the original research enterprise, with a market share of 44.37% Shandong Jingwei Pharmaceutical Co., Ltd ranks the second with a market share of nearly 40% Figure 3: status of enterprises related to the application for conformity assessment of escitalopram tablets (data source: medchina drug review database 2.0 of minenet) According to the current situation, only Hunan Dongting Pharmaceutical Co., Ltd has started the technical assessment for conformity assessment of escitalopram tablets Figure 4: Sales of sertraline hydrochloride tablets in public medical institutions in China in recent years (unit: 10000 yuan) (data source: the terminal competition pattern of China's public medical institutions on the Internet) Figure 5: the brand pattern of sertraline hydrochloride tablets in China's public medical institutions in 2016 (data source: the terminal competition pattern of China's public medical institutions on the Internet) According to the data, in 2016, the sales volume of sertraline hydrochloride tablets in the terminal chemical drug market of public medical institutions in China has exceeded 680 million yuan The leading enterprise in the market is Pfizer, the original research enterprise, with a market share of more than 71% The second domestic enterprise, Zhejiang Jingxin pharmaceutical, has a market share of nearly 11% Figure 6: status of enterprises related to the application for conformity assessment of sertraline hydrochloride tablets (data source: medchina drug review database 2.0 of minenet) From the current situation, only Zhejiang Jingxin Pharmaceutical Co., Ltd has started the technical assessment of conformity assessment of sertraline hydrochloride tablets In 2016, amitriptyline hydrochloride sold 11.04 million yuan in the terminal chemical drug market of public medical institutions in China The main competitors include Changzhou No.4 Pharmaceutical Co., Ltd., Hunan Dongting Pharmaceutical Co., Ltd and Shangyao Xinyi Pharmaceutical Co., Ltd Only Hunan Dongting Pharmaceutical Co., Ltd has started the technical evaluation of amitriptyline hydrochloride tablets consistency   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Top 1 products of psychoactive drugs, with annual sales exceeding 3 billion Figure 7: Sales of olanzapine tablets in public medical institutions in China in recent years (unit: 10000 yuan) (data source: minenet China public medical institutions terminal competition pattern) figure 8: brand pattern of olanzapine tablets in public medical institutions in China in 2016 (data source: the terminal competition pattern of Chinese public medical institutions on the Internet) data shows that in 2016, olanzapine tablets were listed in the top 20 terminal chemical and psychostatic products of Chinese public medical institutions Ranking first, the sales volume has exceeded 3 billion yuan The leading enterprise in the market is Jiangsu Haosen Pharmaceutical Group, with a market share of nearly 67%, while Lilly, the original research manufacturer, ranks second with a market share of more than 21% Figure 9: status of relevant enterprises applying for olanzapine tablet consistency evaluation (data source: Med China drug review database 2.0 on minenet) From the current situation, only Jiangsu Haosen Pharmaceutical Group has started the technical review of olanzapine tablet consistency evaluation   none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> conclusion of the four neurologics mentioned above, except amitriptyline hydrochloride tablets, the other three are non" 289 directory "varieties According to relevant requirements, the "289 catalog" announced that the conformity evaluation varieties of generic drug quality and efficacy must be completed by the end of 2018 For the chemical generic oral solid preparations outside the catalog, the enterprise can organize the conformity evaluation on its own After the first variety passed the conformity evaluation, the enterprise will not accept the application for conformity evaluation of the same variety from other drug manufacturers three years later After the first batch of generic drug conformity evaluation varieties are officially announced, will the relevant competitive enterprises speed up the pace of "getting on the car"? Will the market pattern of these varieties be greatly reversed? There is a large imagination space, and minenet will continue to pay attention to you Source: minenet database, Shenwan Hongyuan Duzhou pharmaceutical team
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.